Hydrogen Therapy Boosts Cancer Treatment in Melanoma Study
- Authors
- Xiang Liu, Weidong Wang, Tianze Wu, Jianing Li, Yimin Gong, Dan Luo, Xianling Guo, Mingli Deng, Yannan Yang
- Journal
- ACS Applied Materials & Interfaces
- Year
- 2025
- DOI
- 10.1021/acsami.5c15739
- Study Type
- Cell Culture
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- China
- Health Condition
- Melanoma
- Body System
- Immune System
TL;DR
A special hydrogen-releasing nanoparticle boosts the effectiveness of cancer immunotherapy by helping immune cells better recognize and attack tumors.
Key Finding
Hydrogen gas delivered via specialized nanoparticles enhanced the effectiveness of cancer immunotherapy drugs, achieving 83-90% tumor inhibition in melanoma models when combined with anti-CD47 and anti-PD-L1 antibodies.
Summary
Researchers developed a nanoparticle system that delivers hydrogen gas directly to tumors to enhance cancer immunotherapy. In laboratory and animal melanoma models, the hydrogen-releasing nanoparticles damaged tumor cells and made them more visible to immune system antibodies. When combined with existing immunotherapy drugs, this approach achieved 83-90% tumor shrinkage, suggesting hydrogen gas delivery may help overcome resistance to standard cancer treatments.
Practical Takeaway
This is early-stage laboratory and animal research, not human studies, so it cannot yet inform consumer decisions about hydrogen water. The study used a specialized nanoparticle delivery system, not the hydrogen water products available to consumers. While the results are promising for future cancer treatments, much more research is needed before any clinical applications would be possible.
Abstract
Identifying strategies to improve the efficacy of the immune checkpoint blockade (ICB) remains a major clinical need. Based on the high tissue penetration capability of hydrogen molecules (H2) and their immunomodulatory effects, this work proposes a local gas delivery strategy targeting the tumor microenvironment for high-efficacy hydrogen immunotherapy. We synthesized hepta-fluorinated zeolitic imidazolate frameworks nanosheet (F7-ZIF) with high H2 payload, sustained acid-responsive gas release property, and biodegradation. H2-loaded F7-ZIF (F7-ZIF/H2) effectively released H2 and Zn2+ to induce significant mitochondrial damage and cell apoptosis. More importantly, F7-ZIF/H2 considerably upregulated the expression of CD47 ("do not eat me" signal) on tumor cells, which increases target accessibility for anti-CD47 antibody, thereby enhancing their binding efficiency. RNA-seq suggests that the CD47 antibody not only blocks the "do not eat me" signal (mediated by CD47-SIRPα interactions) but also engages Fc receptors on macrophages through its Fc region to trigger antibody-dependent cellular phagocytosis. In melanoma tumor models with small (∼50 mm3) and large sized established tumors (∼200 mm3), the combination of F7-ZIF/H2 and anti-CD47 reaches 90% and 83% of tumor inhibition rate, respectively, compared to free anti-CD47. When further combined with anti-PD-L1, the therapeutic system triggers systemic T cell immunity that rejects the progression of both primary and distal tumors. This work provides insights into gas-assisted cancer immunotherapy.